<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39370830</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Molecular epidemiology and vaccine compatibility analysis of seasonal influenza A viruses in the context of COVID-19 epidemic in Wuhan, China.</ArticleTitle><Pagination><StartPage>e29858</StartPage><MedlinePgn>e29858</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29858</ELocationID><Abstract><AbstractText>The COVID-19 pandemic had a significant impact on the global influenza vaccination and the epidemics of seasonal influenza. To further explore the molecular epidemiology of influenza viruses and assess vaccine effectiveness, we collected influenza cases in Wuhan during the 2022-2023 influenza season. Among 1312 clinical samples, 312 samples tested positive for influenza viruses using reverse transcription polymerase chain reaction. These positive samples included 146A/H1N1 subtypes (46.8%), 164A/H3N2 subtypes (52.6%) and 2 influenza B virus types (0.6%). Based on the whole genome sequence information of hemagglutinin (HA) and neuraminidase (NA) from 27A/H1N1 influenza virus strains and 26A/H3N2 influenza virus strains obtained in this study, a phylogenetic analysis was conducted. The analysis revealed that all A/H1N1 strains belonged to the evolutionary branch 6B.1A.5a.2a, and they exhibited specific substitutions at positions K71Q, Q206E, E241A, and R276K. Similarly, all A/H3N2 strains were classified into the 3C.2a1b.2a.1a subclade and displayed amino acid substitutions at positions S172H, N175Y, I176T, K187N, and S214P. Notably, the A/H3N2 strains also acquired a new potential glycosylation site at position N174. Using an epitope model, the predicted vaccine effectiveness was assessed for the A/H1N1 and A/H3N2 strains. The predicted vaccine effectiveness against the Wuhan influenza epidemic strain was over 85% for the A/H1N1 vaccine strain. However, the effectiveness against the A/H3N2 vaccine strain was only 48.7%. To further verify the protection of influenza vaccine against circulating influenza viruses in the region, we conducted in vivo and in vitro animal studies. The results of in vitro neutralization experiment showed that rabbit serum antibodies inoculated with quadrivalent isolated influenza vaccine had neutralization ability against all 24 isolated influenza viruses. In vivo experiments showed that vaccinated mice had fewer lung lesions when infected with the influenza strain circulating in Wuhan, suggesting that vaccination can effectively reduce the occurrence of severe lung damage. These findings emphasize the importance of accurately predicting seasonal influenza strains for effective influenza prevention and control, especially during the co-circulation of SARS-CoV-2 and influenza viruses. This study provides valuable information on the seasonal influenza virus in Wuhan during the COVID-19 pandemic and serves as a basis for vaccine prediction and updates.</AbstractText><CopyrightInformation>© 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Zhikun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Lanxin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Provincial Vaccine Technology Innovation Center, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Jiahao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Provincial Vaccine Technology Innovation Center, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nian</LastName><ForeName>Xuanxuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Provincial Vaccine Technology Innovation Center, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhegang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Provincial Vaccine Technology Innovation Center, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Liangjun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoqi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yirong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5619-1614</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jiayou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wuhan Institute of Biological Products Co. Ltd., Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Key Laboratory for Novel Vaccines Research and Development of Emerging Infectious Diseases, Wuhan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hubei Provincial Vaccine Technology Innovation Center, Wuhan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022023702025187</GrantID><Agency>Science and Technology Program of Wuhan</Agency><Country /></Grant><Grant><GrantID>2022BCA019</GrantID><Agency>Key Research and Development Program of Hubei Province</Agency><Country /></Grant><Grant><GrantID>WSJKRC2022012</GrantID><Agency>2021 Hubei Provincial Leading Public Health Talents Project</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="Y">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="Y">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017720" MajorTopicYN="Y">Molecular Epidemiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">influenza A virus</Keyword><Keyword MajorTopicYN="N">molecular epidemiology</Keyword><Keyword MajorTopicYN="N">phylogenic analysis</Keyword><Keyword MajorTopicYN="N">vaccine effectiveness</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39370830</ArticleId><ArticleId IdType="doi">10.1002/jmv.29858</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hutchinson EC. Influenza virus. TIM. 2018;26(9):809‐810. doi:10.1016/j.tim.2018.05.013</Citation></Reference><Reference><Citation>Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza‐associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285‐1300. doi:10.1016/S0140-6736(17)33293-2</Citation></Reference><Reference><Citation>Baselga‐Moreno V, Trushakova S, McNeil S, et al. Influenza epidemiology and influenza vaccine effectiveness during the 2016‐2017 season in the Global Influenza Hospital Surveillance Network (GIHSN). BMC Public Health. 2019;19(1):487. doi:10.1186/s12889-019-6713-5</Citation></Reference><Reference><Citation>D'angiolella LS, Lafranconi A, Cortesi PA, Rota S, Cesana G, Mantovani LG. Costs and effectiveness of influenza vaccination: a systematic review. Ann Ist Super Sanita. 2018;54(1):49‐57. doi:10.4415/ANN_18_01_10</Citation></Reference><Reference><Citation>Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices ‐ United States, 2022‐23 influenza season. MMWR Recomm Rep. 2022;71(1):1‐28. doi:10.15585/mmwr.rr7101a1</Citation></Reference><Reference><Citation>Trombetta CM, Kistner O, Montomoli E, Viviani S, Marchi S. Influenza viruses and vaccines: the role of vaccine effectiveness studies for evaluation of the benefits of influenza vaccines. Vaccines. 2022;10(5):714. doi:10.3390/vaccines10050714</Citation></Reference><Reference><Citation>Lewnard JA, Cobey S. Immune history and influenza vaccine effectiveness. Vaccines. 2018;6(2):28. doi:10.3390/vaccines6020028</Citation></Reference><Reference><Citation>Gaitonde DY, Moore FC, Morgan MK. Influenza: diagnosis and treatment. Am Fam Physician. 2019;100(12):751‐758.</Citation></Reference><Reference><Citation>Wedde M, Biere B, Wolff T, Schweiger B. Evolution of the hemagglutinin expressed by human influenza A(H1N1)pdm09 and A(H3N2) viruses circulating between 2008‐2009 and 2013‐2014 in Germany. IJMM. 2015;305(7):762‐775. doi:10.1016/j.ijmm.2015.08.030</Citation></Reference><Reference><Citation>Li Y, Bostick DL, Sullivan CB, et al. Single hemagglutinin mutations that alter both antigenicity and receptor binding avidity influence influenza virus antigenic clustering. J Virol. 2013;87(17):9904‐9910. doi:10.1128/JVI.01023-13</Citation></Reference><Reference><Citation>Ali ST, Cowling BJ, Wong JY, et al. Influenza seasonality and its environmental driving factors in mainland China and Hong Kong. Sci Total Environ. 2022;818:151724. doi:10.1016/j.scitotenv.2021.151724</Citation></Reference><Reference><Citation>Chen LJ, Guo JJ, Guo WW, et al. Molecular epidemiology and vaccine compatibility analysis of seasonal influenza viruses in Wuhan, 2016‐2019. Virol Sin. 2020;35(5):556‐565. doi:10.1007/s12250-020-00225-2</Citation></Reference><Reference><Citation>Nickbakhsh S, Mair C, Matthews L, et al. Virus‐virus interactions impact the population dynamics of influenza and the common cold. Proc Nat Acad Sci. 2019;116(52):27142‐27150. doi:10.1073/pnas.1911083116</Citation></Reference><Reference><Citation>Sakamoto H, Ishikane M, Ueda P. Seasonal influenza activity during the SARS‐CoV‐2 outbreak in Japan. JAMA. 2020;323(19):1969‐1971. doi:10.1001/jama.2020.6173</Citation></Reference><Reference><Citation>World Health Organisation, 2021. WHO information for molecular diagnosis of influenza virus.</Citation></Reference><Reference><Citation>Pan K, Subieta KC, Deem MW. A novel sequence‐based antigenic distance measure for H1N1, with application to vaccine effectiveness and the selection of vaccine strains. Protein Eng Des Sel. 2011;24(3):291‐299. doi:10.1093/protein/gzq105</Citation></Reference><Reference><Citation>Bonomo ME, Deem MW. Predicting influenza H3N2 vaccine efficacy from evolution of the dominant epitope. Clin Infect Dis. 2018;67(7):1129‐1131. doi:10.1093/cid/ciy323</Citation></Reference><Reference><Citation>Deem MW, Pan K. The epitope regions of H1‐subtype influenza A, with application to vaccine efficacy. Protein Eng Des Sel. 2009;22(9):543‐546. doi:10.1093/protein/gzp027</Citation></Reference><Reference><Citation>Lee MS, Chen JSE. Predicting antigenic variants of influenza A/H3N2 viruses. Emerg Infect Dis. 2004;10(8):1385‐1390. doi:10.3201/eid1008.040107</Citation></Reference><Reference><Citation>Jiang Y, Tong Y, Fang B, Zhang W, Yu X. Applying the moving epidemic method to establish the influenza epidemic thresholds and intensity levels for age‐specific groups in Hubei Province, China. Int J Environ Res Public Health. 2022;19(3):1677. doi:10.3390/ijerph19031677</Citation></Reference><Reference><Citation>Huo X, Fu J, Dai Q, Zhu F. Influenza virus subtype/lineage‐specific seasonal patterns and age‐related infection risk, in Eastern China. J Infect Develop Ctries. 2022;16(12):1928‐1932. doi:10.3855/jidc.14887</Citation></Reference><Reference><Citation>Muscatello DJ. Redefining influenza seasonality at a global scale and aligning it to the influenza vaccine manufacturing cycle: a descriptive time series analysis. J Infect. 2019;78(2):140‐149. doi:10.1016/j.jinf.2018.10.006</Citation></Reference><Reference><Citation>Yu H, Alonso WJ, Feng L, et al. Characterization of regional influenza seasonality patterns in China and implications for vaccination strategies: spatio‐temporal modeling of surveillance data. PLoS Med. 2013;10(11):e1001552. doi:10.1371/journal.pmed.1001552</Citation></Reference><Reference><Citation>Dhanasekaran V, Sullivan S, Edwards KM, et al. Human seasonal influenza under COVID‐19 and the potential consequences of influenza lineage elimination. Nat Commun. 2022;13(1):1721. doi:10.1038/s41467-022-29402-5</Citation></Reference><Reference><Citation>Caini S, Kusznierz G, Garate VV, et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS One. 2019;14(9):e0222381. doi:10.1371/journal.pone.0222381</Citation></Reference><Reference><Citation>Huang W, Cheng Y, Tan M, et al. Epidemiological and virological surveillance of influenza viruses in China during 2020‐2021. Infect Dis Poverty. 2022;11(1):74. doi:10.1186/s40249-022-01002-x</Citation></Reference><Reference><Citation>Sominina A, Danilenko D, Komissarov AB, et al. Assessing the intense influenza A(H1N1)pdm09 epidemic and vaccine effectiveness in the Post‐COVID season in the Russian Federation. Viruses. 2023;15(8):1780. doi:10.3390/v15081780</Citation></Reference><Reference><Citation>Galli C, Pellegrinelli L, Giardina F, et al. On the lookout for influenza viruses in Italy during the 2021‐2022 season: along came A(H3N2) viruses with a new phylogenetic makeup of their hemagglutinin. Virus Res. 2023;324:199033. doi:10.1016/j.virusres.2022.199033</Citation></Reference><Reference><Citation>Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta‐analysis. Lancet Infect Dis. 2012;12(1):36‐44. doi:10.1016/S1473-3099(11)70295-X</Citation></Reference><Reference><Citation>Östbye H, Gao J, Martinez MR, Wang H, de Gier JW, Daniels R. N‐linked glycan sites on the influenza A virus neuraminidase head domain are required for efficient viral incorporation and replication. J Virol. 2020;94(19):e00874‐20. doi:10.1128/JVI.00874-20</Citation></Reference><Reference><Citation>Cox R. Correlates of protection to influenza virus, where do we go from here? Hum Vaccines Immunother. 2013;9(2):405‐408. doi:10.4161/hv.22908</Citation></Reference><Reference><Citation>Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination‐inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random‐effects model. BMC Med Res Methodol. 2010;10:18. doi:10.1186/1471-2288-10-18</Citation></Reference><Reference><Citation>Ng S, Saborio S, Kuan G, et al. Association between haemagglutination inhibiting antibodies and protection against clade 6B viruses in 2013 and 2015. Vaccine. 2017;35(45):6202‐6207. doi:10.1016/j.vaccine.2017.09.036</Citation></Reference><Reference><Citation>Yang Z, Yu S, Xu Y, et al. The screening and mechanism of influenza‐virus sensitive MDCK cell lines for influenza vaccine production. Diseases. 2024;12(1):20. doi:10.3390/diseases12010020</Citation></Reference><Reference><Citation>Yang L, Li G, Yang J, et al. Deep‐learning model for influenza prediction from multisource heterogeneous data in a megacity: model development and evaluation. J Med Internet Res. 2023;25:e44238. doi:10.2196/44238</Citation></Reference><Reference><Citation>Lee J, Hadfield J, Black A, et al. Joint visualization of seasonal influenza serology and phylogeny to inform vaccine composition. Front Bioinform. 2023;3:1069487. doi:10.3389/fbinf.2023.1069487</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>